HALF-YEARLY REPORT ON THE LIQUIDITY CONTRACT WITH INVEST SECURITIES Berlin, Germany, January 16, 2020, 06.00 p.m. CET - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that pursuant to the liquidity contract entrusted to Invest Securities by NOXXON Pharma N.V. the following assets appeared on the liquidity account: As of December 31, 2019: Number of shares: 14,540 Cash balance of the liquidity account: EUR 31,119.15 For the period July 1, 2019 - December 31, 2019: o Total number of shares bought: 88,633...
|